Washout periods for brimonidine 0.2% and latanoprost 0.005%

被引:50
|
作者
Stewart, WC
Holmes, KT
Johnson, MA
机构
[1] Pharmaceut Res Corp, Charleston, SC 29412 USA
[2] Univ S Carolina, Sch Med, Carolina Eye Inst, Columbia, SC USA
[3] Atlanta Res Co LLC, Atlanta, GA USA
关键词
D O I
10.1016/S0002-9394(00)00930-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the intraocular pressure washout time after discontinuing brimonidine 0.2% twice daily and latanoprost 0.005% once every evening. METHODS: We discontinued brimonidine or latanoprost in a masked fashion from primary open-angle glaucoma or ocular hypertensive patients. The intraocular pressure was measured twice weekly until patients returned to untreated baseline. RESULTS: In 32 patients, the mean longest eye washout time for brimonidine (n = 15) was 3.3 +/- 3.0 weeks and for latanoprost (n = 17) was 4.4 +/- 3.2 weeks (P = .24) In all but one patient, brimonidine returned to baseline by 5 weeks and latanoprost returned by 8 weeks. CONCLUSION: After discontinuing latanoprost or brimonidine, a wide variation exists in washout times among individuals, with latanoprost demonstrating a trend to a longer washout period, (Am J Ophthalmol 2001;131: 798-799. (C) 2001 by Elsevier Science Inc. All rights reserved.).
引用
收藏
页码:798 / 799
页数:2
相关论文
共 50 条
  • [22] Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension
    Mundorf, Thomas
    Noecker, Robert J.
    Earl, Melissa
    ADVANCES IN THERAPY, 2007, 24 (02) : 302 - 309
  • [23] Sympathetic use of latanoprost 0.005% in 30 eyes
    Montrone, F
    Macinagrossa, G
    Tenerelli, F
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1998, 76 : 38 - 39
  • [24] The effect of 0.005% Latanoprost on anterior ocular structures
    Marchini, G
    Marraffa, M
    Ghilotti, G
    Bonadimani, M
    Bonomi, L
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1999, 77 : 50 - 50
  • [25] Brimonidine and latanoprost as adjunctive therapy - Author reply
    Simmons, ST
    Earl, M
    OPHTHALMOLOGY, 2003, 110 (01) : 8 - 9
  • [26] Chemical Analysis of Branded Latanoprost 0.005% Compared With Commercially Available Latanoprost Formulations
    Lu, D.
    Hong, L.
    Xu, X.
    Weber, S.
    Pokabla, M.
    Hein, A.
    Noecker, R.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [27] Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma
    Simmons, ST
    Samuelson, TW
    CLINICAL THERAPEUTICS, 2000, 22 (04) : 388 - 399
  • [28] The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts
    Lark, KK
    Pasha, AS
    Yan, XM
    Edward, DP
    JOURNAL OF GLAUCOMA, 1999, 8 (01) : 72 - 76
  • [29] Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles
    Halder, Arindam
    Khopade, Ajay J.
    CURRENT EYE RESEARCH, 2021, 46 (07) : 1031 - 1037
  • [30] Pharmacokinetics (PK) of Latanoprost Acid in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%
    Raber, S.
    Courtney, R.
    Maeda-Chubachi, T.
    Simons, B. D.
    Freedman, S.
    Wirostko, B. M.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)